The evolution of N, N-Dimethyltryptamine: from metabolic pathways to brain connectivity
- PMID: 40210737
- DOI: 10.1007/s00213-025-06777-z
The evolution of N, N-Dimethyltryptamine: from metabolic pathways to brain connectivity
Abstract
Rationale: N, N-Dimethyltryptamine (DMT), a potent serotonergic psychedelic, bridges ancient wisdom and modern science. The mechanisms underlying its powerful psychedelic effects and out-of-body experiences continue to intrigue scientists. The functional role of DMT remains ambiguous. This paper explores the endogenous presence of DMT in the human body and its diverse neuroregulatory functions, which influence hierarchical brain connectivity, and the mechanisms driving its psychedelic effects.
Objective: This paper aims to analyze DMT-receptor binding, its effects on neuronal modulation, brain oscillations, and connectivity, and its influence on hallucinations, out-of-body experiences, and cognitive functions.
Results: DMT administration induces significant changes in brain wave dynamics, including reduced alpha power, increased delta power, and heightened Lempel-Ziv complexity, reflecting enhanced neural signal diversity. Functional neuroimaging studies reveal that DMT enhances global functional connectivity (GFC), particularly in transmodal association cortices such as the salience network, frontoparietal network, and default mode network, correlating with ego dissolution. The receptor density-dependent effects of DMT were mapped to brain regions rich in serotonin 5-HT2A receptors, supporting its role in modulating consciousness and neuroplasticity.
Conclusion: This integrated analysis provides insights into the profound effects of DMT on human cognition, and consciousness, and its role in enhancing natural well-being. As we uncover the endogenous functions of DMT, it becomes clear that the study of its biology reveals a complex interplay between brain chemistry and consciousness.
Keywords: Cognition; Endogenous DMT; Exogenous DMT; Global neural network; Neurotransmitter; Psychedelic.
© 2025. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Conflict of interest statement
Declarations. Ethical approval: Not applicable. Competing interest: The authors have no competing interests to declare relevant to this article's content.
Similar articles
-
Neurochemical and Neurophysiological Effects of Intravenous Administration of N,N-Dimethyltryptamine in Rats.bioRxiv [Preprint]. 2025 Feb 15:2024.04.19.589047. doi: 10.1101/2024.04.19.589047. bioRxiv. 2025. PMID: 38712161 Free PMC article. Preprint.
-
Human brain effects of DMT assessed via EEG-fMRI.Proc Natl Acad Sci U S A. 2023 Mar 28;120(13):e2218949120. doi: 10.1073/pnas.2218949120. Epub 2023 Mar 20. Proc Natl Acad Sci U S A. 2023. PMID: 36940333 Free PMC article.
-
Increased functional connectivity between brain regions involved in social cognition, emotion and affective-value in psychedelic states induced by N,N-Dimethyltryptamine (DMT).Front Pharmacol. 2024 Oct 30;15:1454628. doi: 10.3389/fphar.2024.1454628. eCollection 2024. Front Pharmacol. 2024. PMID: 39539622 Free PMC article.
-
N, N-dimethyltryptamine (DMT) in rodent brain: Concentrations, distribution, and recent pharmacological data.Prog Neuropsychopharmacol Biol Psychiatry. 2025 Mar 20;137:111259. doi: 10.1016/j.pnpbp.2025.111259. Epub 2025 Jan 19. Prog Neuropsychopharmacol Biol Psychiatry. 2025. PMID: 39832749 Review.
-
Neurobiological research on N,N-dimethyltryptamine (DMT) and its potentiation by monoamine oxidase (MAO) inhibition: from ayahuasca to synthetic combinations of DMT and MAO inhibitors.Cell Mol Life Sci. 2024 Sep 10;81(1):395. doi: 10.1007/s00018-024-05353-6. Cell Mol Life Sci. 2024. PMID: 39254764 Free PMC article. Review.
Cited by
-
Novel Ergolines as 5‑HT2A Agonists for Treating Mood Disorders.ACS Med Chem Lett. 2025 May 21;16(6):974-975. doi: 10.1021/acsmedchemlett.5c00288. eCollection 2025 Jun 12. ACS Med Chem Lett. 2025. PMID: 40529079
-
Novel Phenylalkylamines as 5‑HT2A Agonists for Treating Psychiatric Disorders.ACS Med Chem Lett. 2025 May 14;16(6):948-949. doi: 10.1021/acsmedchemlett.5c00269. eCollection 2025 Jun 12. ACS Med Chem Lett. 2025. PMID: 40529051
-
Novel Substituted Pyrazoles as 5‑HT1A Agonists for Treating Neuropsychiatric Diseases.ACS Med Chem Lett. 2025 Jun 3;16(6):978-979. doi: 10.1021/acsmedchemlett.5c00306. eCollection 2025 Jun 12. ACS Med Chem Lett. 2025. PMID: 40529086
-
Novel Indole Derivatives as Serotonergic Psychedelic Agents for Treating Psychosis, Mental Illness, and CNS Disorders.ACS Med Chem Lett. 2025 May 30;16(6):982-983. doi: 10.1021/acsmedchemlett.5c00309. eCollection 2025 Jun 12. ACS Med Chem Lett. 2025. PMID: 40529050
-
Novel Desamide Isotryptamine Tetracycles as 5‑HT2C Agonists for Treating Brain Disorders.ACS Med Chem Lett. 2025 May 21;16(6):976-977. doi: 10.1021/acsmedchemlett.5c00286. eCollection 2025 Jun 12. ACS Med Chem Lett. 2025. PMID: 40529093
References
-
- Acosta-Urquidi J (2015) QEEG studies of the acute effects of the visionary tryptamine DMT. Cosmos Hist J Nat Soc Philos 11(2):115–129
-
- Aghajanian GK, Marek GJ (1997) Serotonin induces excitatory postsynaptic potentials in apical dendrites of neocortical pyramidal cells. Neuropharmacology 36(4–5):589–599. https://doi.org/10.1016/s0028-3908(97)00051-8 - PubMed
-
- Aghajanian GK, Marek GJ (1999) Serotonin, via 5-HT2A receptors, increases EPSCs in layer V pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release. Brain Res 825(1–2):161–171. https://doi.org/10.1016/S0006-8993(99)01224-X - PubMed
-
- Aghajanian GK, Foote WE, Sheard MH (1970) Action of psychotogenic drugs on single midbrain raphe neurons. J Pharmacol Exp Ther 171(2):178–187 - PubMed
-
- Alamia A, Timmermann C, Nutt DJ, VanRullen R, Carhart-Harris RL (2020) DMT Alters Cortical Travelling Waves. elife 9:e59784. https://doi.org/10.7554/eLife.59784 - PubMed - PMC
Publication types
LinkOut - more resources
Full Text Sources
Research Materials